Icon

EXJADE (nda021882)- (125MG,250MG,500MG)

DEFERASIROX NOVARTIS
125MG,250MG,500MG
Yes No
2019-Apr-05 2010-Nov-02
2012-Nov-02 None
None No
Exjade is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L.
9 1 7
Total Other Developers 5
Drugs with Suitability No
125MG ** ** - - -
250MG ** ** - - -
500MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 6
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******** ****** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***, ******* ****** ***** *****, *******, ******, *****, ***** & *** ******, ***** (***) ***
****** ********** ***** ****** *** *********** *** *** *** ********* ** ***** *, *, *-* & *, **********, *** ****** (**) *****-****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.